Short-term autophagy inhibition by autophinib or SAR405 does not alter the effect of cisplatin on ATP production in prostate cancer cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F24%3A00081027" target="_blank" >RIV/00159816:_____/24:00081027 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00136137 RIV/62156489:43210/24:43925208 RIV/00216208:11110/24:10479787

Výsledek na webu

<a href="https://www.elis.sk/download_file.php?product_id=8175&session_id=t8bundg77sctimpic2mqfl68v2" target="_blank" >https://www.elis.sk/download_file.php?product_id=8175&session_id=t8bundg77sctimpic2mqfl68v2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4149/BLL_2024_013" target="_blank" >10.4149/BLL_2024_013</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Short-term autophagy inhibition by autophinib or SAR405 does not alter the effect of cisplatin on ATP production in prostate cancer cells

Popis výsledku v původním jazyce

OBJECTIVES: Cisplatin is a widely used anticancer drug for the treatment of many solid cancers. DNA damage is thought to be the key mechanism of cisplatin&apos;s anticancer activity. However, cisplatin may also affect cellular metabolism. The aim of this study was to determine the effect of cisplatin on the types of ATP production (OXPHOS versus glycolysis) and their rate in prostate cancer cells and to determine the potentially protective effect of autophagy and amino acids during cisplatin treatment. We also wanted to investigate the potential synergy between the metabolic effects of cisplatin on ATP production and the inhibition of autophagy. METHODS: We used two models of autophagy inhibition, a natural model of dysfunctional autophagy-DU145 cells and 24 -hour inhibition of autophagy by autophinib or SAR405. The effect of cisplatin and autophagy inhibition was observed on prostate cancer cell lines 22Rv1, PC -3, and DU145. To assess the type (OXPHOS versus glycolysis) and rate of ATP production, the Seahorse XF Real -Time ATP Rate Assay was performed by measuring the extracellular acidification rates (ECAR) as a proxy for glycolytic readouts and the oxygen consumption rates (OCR) as a proxy for oxidative phosphorylation readouts. We also performed quantitative phase imaging and colony -forming assay to assess the metastatic potential of cancer cells. Finally, amino acid profiles were examined using ion -exchange liquid chromatography. RESULTS: After cisplatin treatment, ATP production by OXPHOS was significantly decreased in 22Rv1 and PC -3 cells. On the other hand, ATP production by glycolysis was not significantly affected in 22Rv1 cells. DU145 cells with dysfunctional autophagy were the most sensitive to cisplatin treatment and showed the lowest ATP production. However, short-term autophagy inhibition (24h) by autophinib or SAR405 in 22Rv1 and PC -3 cells did not alter the effect of cisplatin on ATP production. Levels of some amino acids (arginine, methionine) significantly affected the fitness of cancer cells. CONCLUSION: Persistent defects of autophagy can affect the metabolic sensitivity of cancer cells due to interference with arginine metabolism. Amino acids contained in the culture medium had an impact on the overall effect of cisplatin (Fig. 3, Ref. 38). Text in PDF www.elis.sk

Název v anglickém jazyce

Short-term autophagy inhibition by autophinib or SAR405 does not alter the effect of cisplatin on ATP production in prostate cancer cells

Popis výsledku anglicky

OBJECTIVES: Cisplatin is a widely used anticancer drug for the treatment of many solid cancers. DNA damage is thought to be the key mechanism of cisplatin&apos;s anticancer activity. However, cisplatin may also affect cellular metabolism. The aim of this study was to determine the effect of cisplatin on the types of ATP production (OXPHOS versus glycolysis) and their rate in prostate cancer cells and to determine the potentially protective effect of autophagy and amino acids during cisplatin treatment. We also wanted to investigate the potential synergy between the metabolic effects of cisplatin on ATP production and the inhibition of autophagy. METHODS: We used two models of autophagy inhibition, a natural model of dysfunctional autophagy-DU145 cells and 24 -hour inhibition of autophagy by autophinib or SAR405. The effect of cisplatin and autophagy inhibition was observed on prostate cancer cell lines 22Rv1, PC -3, and DU145. To assess the type (OXPHOS versus glycolysis) and rate of ATP production, the Seahorse XF Real -Time ATP Rate Assay was performed by measuring the extracellular acidification rates (ECAR) as a proxy for glycolytic readouts and the oxygen consumption rates (OCR) as a proxy for oxidative phosphorylation readouts. We also performed quantitative phase imaging and colony -forming assay to assess the metastatic potential of cancer cells. Finally, amino acid profiles were examined using ion -exchange liquid chromatography. RESULTS: After cisplatin treatment, ATP production by OXPHOS was significantly decreased in 22Rv1 and PC -3 cells. On the other hand, ATP production by glycolysis was not significantly affected in 22Rv1 cells. DU145 cells with dysfunctional autophagy were the most sensitive to cisplatin treatment and showed the lowest ATP production. However, short-term autophagy inhibition (24h) by autophinib or SAR405 in 22Rv1 and PC -3 cells did not alter the effect of cisplatin on ATP production. Levels of some amino acids (arginine, methionine) significantly affected the fitness of cancer cells. CONCLUSION: Persistent defects of autophagy can affect the metabolic sensitivity of cancer cells due to interference with arginine metabolism. Amino acids contained in the culture medium had an impact on the overall effect of cisplatin (Fig. 3, Ref. 38). Text in PDF www.elis.sk

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30200 - Clinical medicine

Projekt

<a href="/cs/project/NU21-03-00223" target="_blank" >NU21-03-00223: Vliv metabolického reprogramování fibroblastů asociovaných s nádorem na prognózu pacientů s nádory hlavy a krku</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bratislava Medical Journal-Bratislavske Lekarske Listy

ISSN

0006-9248

e-ISSN

1336-0345

Svazek periodika

125

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

8

Strana od-do

84-91

Kód UT WoS článku

001202183600010

EID výsledku v databázi Scopus

—